Clinical TrialJul 22, 2026, 05:31 PM
Bluejay Diagnostics Completes SYMON-II Clinical Trial Enrollment for 750 Patients
AI Summary
Bluejay Diagnostics, Inc. announced the successful completion of patient enrollment in its SYMON-II multicenter clinical validation study. The study enrolled 750 patients, achieving its target ahead of schedule, to evaluate the Symphony™ IL-6 test for assessing 28-day all-cause mortality risk in sepsis patients. This milestone provides a robust clinical dataset, with a preliminary 17% 28-day mortality rate observed, which is critical for the company's planned regulatory submissions and commercialization strategy.
Key Highlights
- Completed patient enrollment in SYMON-II multicenter clinical validation study.
- Enrolled 750 patients for the SYMON-II study, ahead of original schedule.
- SYMON-II evaluates Symphony™ IL-6 for early assessment of 28-day sepsis mortality risk.
- Preliminary observations show approximately 17% 28-day mortality rate in enrolled population.
- Data from SYMON-II will support future regulatory submissions and commercialization efforts.
Price Impact
More from BJDX